Cargando…

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma

INTRODUCTION: KRAS mutation is a common occurrence in Pancreatic Ductal Adenocarcinoma (PDA) and is a driver mutation for disease development and progression. KRAS wild-type PDA may constitute a distinct molecular and clinical subtype. We used the Foundation one data to analyze the difference in Gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashok Kumar, Prashanth, Serinelli, Serenella, Zaccarini, Daniel J., Huang, Richard, Danziger, Natalie, Janovitz, Tyler, Basnet, Alina, Sivapiragasam, Abirami, Graziano, Stephen, Ross, Jeffrey S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315669/ https://www.ncbi.nlm.nih.gov/pubmed/37404765 http://dx.doi.org/10.3389/fonc.2023.1169586

Ejemplares similares

Ductal Adenocarcinoma Ex Pleomorphic Adenoma of the Lacrimal Gland: a Rare and Morbid Malignancy
por: Ashok Kumar, Prashanth, et al.
Publicado: (2020)

Molecular Targets in Salivary Gland Cancers: A Comprehensive Genomic Analysis of 118 Mucoepidermoid Carcinoma Tumors
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss
por: Bou Zerdan, Maroun, et al.
Publicado: (2023)

Primary Mucinous Adenocarcinoma of the Upper Eyelid in an African American Female: A Rare Clinical Entity. A Case Report and Literature Review
por: Ashok Kumar, Prashanth, et al.
Publicado: (2019)

Synovial sarcoma of the hand-wrist: a case report and review of the literature
por: Serinelli, Serenella, et al.
Publicado: (2021)

Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer
por: Basnet, Alina, et al.
Publicado: (2017)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study
por: Ashok Kumar, Prashanth, et al.
Publicado: (2021)

Current Trends in the Management of Epithelial Lacrimal Gland Tumors: A Retrospective National Cancer Database Analysis
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Genomic landscape of non‐small‐cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature
por: Sandhu, Michael, et al.
Publicado: (2023)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma
por: Avila, Jacqueline L., et al.
Publicado: (2012)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
por: Ardalan, Bach, et al.
Publicado: (2021)

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016)

Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma
por: Roy, Shikha, et al.
Publicado: (2021)

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
por: PENG, JIE, et al.
Publicado: (2013)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
por: Ali, Ahmad, et al.
Publicado: (2022)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023)

Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo
por: Qiu, Wanglong, et al.
Publicado: (2011)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma
por: Alhenc-Gelas, Marion, et al.
Publicado: (2019)

Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
por: Peng, Xinyi, et al.
Publicado: (2023)

Genetic landscape of prognostic value in pancreas ductal adenocarcinoma microenvironment—reply
por: Pu, Ning, et al.
Publicado: (2020)

Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
por: Ciernikova, Sona, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pna4pskv09ojrcrj52rjslp5ho